化疗毒性反应英文

Toxicity of Chemotherapy—The Last Decade In October 1992 Dr Michael Perry was Guest Editor for anissue of Seminars in Oncology devoted to chemotherapy tox jou be the for tum 19 Sem of an the tiv ici mi do dis an tox ap rip de com ity to the rol itie kidneys) review both drugs that have been available for years and those approved in the past decade. Payne and colleagues de rel pic Sh the up Do the suc the dro ing of for de wh Re 1. 2. Volume 33, Number 1 February 2006 009 doi icity, and that issue was published a decade after a similar rnal issue devoted to the topic.1,2 Since then, a large num- r of antitumor agents have been approved for marketing in United States, and most of these agents are now available routine clinical use around the world. In fact, more anti- or agents have probably been approved for marketing in 95 to 2005 than in any other previous decade. This issue of inars is also devoted to chemotherapy toxicity, but many the more recently approved agents are emphasized. Ng and colleagues have discussed cardiotoxicity of agents d presented updated information on the cardiotoxicity of anthracyclines. With the availability of the cardioprotec- e agent dexrazoxane in the past decade, this form of tox- ty of the anthracyclines can now be prevented or mini- zed even when these agents are given at greater cumulative ses than are usually considered safe. These authors also cuss trastuzumab (another new agent in the past decade) d what has been learned regarding its potential for cardio- icity in the settings of both metastatic and adjuvant ther- y of breast cancer. Hausheer and coauthors have reviewed the topic of pe- heral neuropathy caused by antitumor agents in great pth. In his role as the Chief Executive Officer of a drug pany developing an agent to protect against such toxic- , Dr Hausheer has perhaps devoted more time and energy researching this topic than any other medical oncologist in world, particularly regarding how a set of subjective neu- ogic symptoms and their cumulative impairment of activ- s of daily living can be accurately assessed in serial fashion. The articles on toxicity to major organs (liver, lungs, and 3-7754/06/$-see front matter © 2006 Elsevier Inc. All rights reserved. :10.1053/j.seminoncol.2005.11.017 voted their paper to the dermatologic toxicity of the agents eased for marketing in the past decade and have provided tures of some representative examples of such toxicity. ahab, Haider, and Doll provide an encyclopedic review of vascular toxicity of cancer chemotherapeutic agents and date previous publications on the topic authored by Dr ll. Myelotoxicity and gastrointestinal toxicity are reviewed in context of the multiple new agents available to assuage h toxicity, such as the hematopoietic growth factors and agents that selectively block serotonin 5-HT3 (5-hy- xytrytamine) receptors and minimize nausea and vomit- . Finally, Goolsby and Lombardo discuss the management extravasation of chemotherapeutic agents. Although this m of drug toxicity is fortunately rare, when it does occur, vastating surface tissue destruction is often the result, ich may require plastic surgical repair. Raymond B. Weiss, MD Clinical Professor of Medicine Lombardi Cancer Center Georgetown University Medical Center Washington, DC E-mail: RayWeissMD@aol.com ferences Perry MC (ed): Toxicity of chemotherapy. Semin Oncol 19:453-609, 1992 Perry MC (ed): Toxicity of chemotherapy. Semin Oncol 9:1-154, 1982 1